The company’s mission is to tackle cancers with substantial unmet need and few targeted treatment options, by reinventing the traditional approach to target and drug discovery to identify novel biomarker-stratified medicines. 

Spun out of the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of development, Mosaic has active programmes across a variety of oncology indications and disease biology pathways.